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The use of this global
data will be modified
by the local situation,
but it cannot be
ignored.
It is conceivable that
new knowledge of
how to improve the
outcome of diabetic
patients will come
from locales where
default surgery is not
available and where
the “necessity” of chal-
lenging the gold stan-
dard of surgery is “the
mother of invention”
of new nonsurgical
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Think Globally, Act Locally
The advice to think about the big picture, but to act on the situation at hand, has been
applied to politics, business, and other fields. It is also applicable in medicine. When we obtain
evidence that seems globally compelling, how do we apply it to the local situation? ST-
segment elevation myocardial infarction (STEMI) is a case in point. The guidelines on both
sides of the Atlantic are very clear that primary percutaneous coronary intervention (PCI) is
the treatment of choice; but when it is not available, it is useless to lecture about how it is to
be done in all cases. Other approaches to local problems which exist in much of the world
must be perfected, and there are many examples.
Often I find myself asked to give lectures on various topics including the choice of
therapy for patients with diabetes. I have been interested in this subject ever since we saw a
trend in favor of better outcomes with surgery in the EAST trial and were subsequently
convinced by the BARI trial that this was a real problem for balloon angioplasty. As a member
of the Steering Committee of the BARI 2D and FREEDOM trials, I have tried to explain
how the evidence obtained should be used to inform practice. Sometimes practice changes and
the global thinking is applied to the local situation, and sometimes not. Is failure to get with
the guidelines always a failure?
I recently returned from the China Interventional Therapeutics (CIT) meeting in Beijing.
Among my assignments were a couple of lectures on the choice of revascularization for
patients with multivessel coronary disease and diabetes. PCI is exploding in China, as are
many other things, but bypass surgery is not one of them. There are superb surgical centers in
China but they are not widely distributed and, for many reasons, PCI is strongly favored by
the physicians and the patients. I was keenly aware of that, but facts are facts, and the
FREEDOM trial results are what they are. The various risk scores being developed to predict
outcomes using the evidence we have, including FREEDOM and the diabetic subset of
SYNTAX, point to the growing interest in including this data and in informed consent
discussions. How should the 5-year actuarial data from FREEDOM—showing an expected
mortality of 16.3% with PCI and 10.9% with coronary artery bypass grafting (CABG)—be
used in determining treatment choices? The use of this global data will be modified by the
local situation, but it cannot be ignored. (It is on the Internet for all to see.) Nuances about
the trial and other data will continue to evolve, but that is not the point. We have evidence
from a large international trial, and the question is: “what will we do with this evidence?”
As I discussed this issue with colleagues from China and elsewhere over beers in the bar, it
became evident that the response to such evidence cannot be uniformly applied. Surgery for
multivessel disease patients with diabetes is not going to become the standard of care in China
in the near term. What is the reason? Is the evidence collected outside China valid for Chinese
patients? Probably so. Are other advances such as second-generation drug-eluting stents or
functional guidance of interventional procedures going to reverse the evidence? Hopefully these
techniques will improve survival of the patients, but that is just speculation at this point. The
real reason that surgery is not the default strategy for diabetic patients with extensive
multivessel disease in China is the fact that CABG surgery is rarely performed in hospitals in
China. Whereas making surgery the default strategy for such patients may be attractive in the
locales that made up the global results of the FREEDOM trial, this will not be the case where
surgery is not well established. It occurs to me that since the easy solution, i.e., “send them all
to surgery,” is not going to happen everywhere, there is an opportunity to learn much from
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538these “local” experiences. The fact remains that from
BARI to FREEDOM, expert CABG surgery has set the
gold standard for outcomes in diabetic patients with
extensive coronary artery disease. In locales where PCI is
to remain dominant for these patients, the challenge will
be to replicate these surgical results. Can it be done with
more careful selection, meticulous techniques, enhanced
surveillance, or better secondary preventive therapy? I do
not know, but the only way that we will know is for these
patients to be carefully characterized in prospective
registries with long-term follow-up. Is it a cop-out to
advocate registries when many would say that a
randomized controlled trial is the only way to establish
whether therapeutic improvements are having an effect?
Certainly randomized controlled trials are beginning to be
performed in China, and there is rapid progress in the
infrastructure to perform these studies. However, thesurgical penetration outside of a few major centers will
limit the application of evidence obtained to the real-
world practice. It is conceivable that new knowledge of
how to improve the outcome of diabetic patients will
come from locales where default surgery is not available
and where the “necessity” of challenging the gold
standard of surgery is “the mother of invention” of new
nonsurgical therapies. There certainly will be no shortage
of subjects for this investigation as China and India vie
for the dubious title of “diabetic capital of the world.”
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